CDX Regulatory News

ECHA Advances Work on Proposed PFAS Restriction

March 12, 2026

The European Chemicals Agency (ECHA) has taken an important step forward in the regulatory process for per‑ and polyfluoroalkyl substances (PFAS). ECHA’s Committee for Socio‑Economic Analysis (SEAC) has agreed its draft opinion on the proposed EU‑wide restriction covering the manufacture, placing on the market, and use of PFAS.
The draft opinion is based on an extensive assessment of the socio‑economic impacts of a potential PFAS restriction, including an evaluation of costs, benefits, and the availability of alternatives. SEAC’s work builds on the restriction proposal submitted by authorities from Denmark, Germany, the Netherlands, Norway, and Sweden, which addresses all PFAS and all uses.
This development follows the adoption of the final opinion by ECHA’s Risk Assessment Committee (RAC) in early March, which focused on the risks PFAS pose to human health and the environment.
As a next step, SEAC’s draft opinion will be published for a 60‑day public consultation, allowing stakeholders to provide additional input. After reviewing relevant feedback, SEAC is expected to adopt its final opinion by the end of 2026. Both final committee opinions will then be submitted to the European Commission, which will decide on the way forward under the REACH regulatory process.
More information is available on the ECHA website. 

Identify PFAS risks in your supply chain

Thousands of PFAS substances face restrictions globally, and regulations change fast. CDX maps your product portfolio for PFAS exposure, analyzes concentration levels, and flags compliance gaps before they become costly problems.

Learn how CDX helps with PFAS compliance

Other News You May Be Interested In
 

October 23, 2026
ECHA Starts ELV Substances of Concern Work
October 23, 2026
New EUDR Information System Training Dates Available for November
October 21, 2026
Council Supports EPR Simplification for Small Packaging Producers

Stay informed. Get the latest regulatory updates, compliance insights, and CDX news delivered to your inbox.

Subscribe to our Newsletter